Author

Alponce Liyoyo

Observed name: A Liyoyo

Institutions: Kilimanjaro Clinical Research Institute, Government of Tanzania

Observed institutions: Kilimanjaro Clinical Research Institute, Government of Tanzania

OpenAlex ID: A5108300285

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

2023 · A Dierig, M Hoelscher, et al. · Trials · 17

PA-388 Placement for transformative clinical trial skills to sustain chain reaction-like model of expanding human capital for accelerating development of safe, efficacious, accessible and affordable anti-tuberculosis

2023 · Hamu Mlyuka, Alponce Liyoyo, et al.

Works count: 2

Citation count: 17

H-index: 1

I10-index: 1